[Korea Biotech News] Helixmith News

Helixmith, announced on 14th that it has recruited overseas experts and reorganized its clinical organization. The company has reinforced its professional workforce to conduct a new clinical trial after failing to Phase 3 clinical trials of NGD gene therapy drug, NGD, last year. Helixmis's overseas experts are Dr. William Frank, an internal medicine specialist and …

[Korea Biotech News] Helixmith News

Helixmith, whose clinical trial phase 3 failed due to the mixing test and placebo (false drugs), announced on Monday that its release of its findings on its failure would be delayed for another month. This is because drug samples took longer than expected to arrive in the United States, and some analyzes were blinded and …

Foreign Exchange Transaction Law and ICO

Many block-chain project teams recognize ICO (Cryptographic Decommissioning) as a necessary step to raise funds for development, such as platforms. But in Korea, ICO is banned virtually, and the ICO team faces foreign exchange problems since the Foreign Exchange Transactions Act can be applied. According to the regulatory definitions and interpretations of the authorities, business …

ICO in Singapore

Singapore's position on ICO is that it does not put restriction on ICO if it is a bona fide business. In this regard, Singapore's ICO regulatory authority, the Monetary Authority of Singapore, issued several guidelines and announced ICO-related regulations and procedures in Singapore. (You can see the Singapore's government website for consumers.) The SFA applies …